Ning De Shi

Researchers are studying the role of HPV integration in predicting the prognosis of young women aged 45 and below diagnosed with cervical intraepithelial neoplasia grade 2 CIN2, a precancerous cervical condition. The study aims to explore the correlation between HPV integration, vaginal flora changes, and cervical cytology results to better understand disease progression and outcomes. This multi-center cohort study includes 300 participants from hospitals in China, focusing on the natural course of CIN2 without surgical or medication treatment when appropriate. Participants will be followed at enrollment and then at 3, 6, 9, and 12 months. At these visits, HPV viral integration tests, HPV genotyping tests, cervical cytology, and sequencing of vaginal secretions will be performed. Colposcopies and biopsies will be conducted at 6 and 12 months to closely monitor cervical tissue changes. The study observes participants under regular clinical follow-up without intervention unless disease progression occurs. During the study, participants will provide cervical secretions and exfoliated cell samples for testing. Researchers will assess cervical histopathology, HPV integration status, cervical cytology, vaginal flora diversity, and HPV genotyping at multiple time points. Outcomes measured include cervical tissue changes and HPV-related markers to evaluate the diseases natural course. The study lasts 12 months with scheduled clinical visits and laboratory assessments to monitor participants cervical health and HPV status throughout this period.

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.

Researchers are conducting a multicenter, prospective observational study to evaluate how well artificial intelligence AI models using pre-treatment dynamic contrast-enhanced MRI DCE-MRI can predict the benefit of neoadjuvant chemotherapy in women with hormone receptor-positive, HER2-negative HRHER2- breast cancer. The study aims to stratify patients into groups with high or low expected benefit from chemotherapy and assess outcomes such as residual cancer burden and long-term survival. Participants receive routine standard neoadjuvant chemotherapy and undergo pre-treatment breast DCE-MRI scans. The AI model analyzes these images to categorize patients into high-benefit or low-benefit subgroups. Data collected include baseline clinical and pathological information, chemotherapy regimens, and post-surgery residual cancer classifications. The study evaluates response rates and survival outcomes up to five years after surgery. During the study, participants provide clinical data and imaging before starting chemotherapy. After treatment and surgery, researchers measure residual cancer burden and objective tumor response. Long-term follow-up tracks disease-free and overall survival for up to 60 months. The main outcome is the rate of minimal residual cancer after chemotherapy, helping to verify the AI models usefulness for individualized treatment selection in this breast cancer population.

Researchers are studying cervical neuroendocrine tumors by collecting clinical diagnosis and treatment data from 300 patients. This includes information like age, biopsy results, histopathology, and follow-up survival data. The goal is to analyze the molecular characteristics and prognosis of this cancer type to better understand its behavior and potential clinical applications. The study also gathers paraffin tissue samples from 100 cases across multiple centers to perform protein concentration and omics analyses. These tests help establish molecular features and identify prognostic markers of cervical neuroendocrine tumors. Participants medical and follow-up data are reviewed to assess outcomes such as mortality rate and disease-free survival within three years after surgery. The study builds a database to support ongoing research and analysis of cervical neuroendocrine tumors protein profiles and patient prognosis.